The lack of a truly effective diagnostic test for brain injury is a major unmet need in modern medicine. Therefore, it is critical that a core group of TBI biomarkers be identified. Our overall project is to clinically validate the diagnostic test based on glycan-based biomarker(s) found in one of the body fluids for diagnosing TBI and stroke. The company's aim is to licence out the product to a major pharma company for further development.